Sponsors (8)
Introduced January 22, 2026 by H. Morgan Griffith · Last progress January 22, 2026
The bill establishes clearer federal rules and stronger FDA/HHS authority to protect public health and create regulatory certainty for compliant products, but it imposes new compliance costs, enforcement powers, and potential access restrictions that will notably burden small businesses and some consumers.
Manufacturers, retailers, and consumers gain a clearer, consistent federal regulatory framework for hemp-derived cannabinoid products (definitions, labeling, testing, and which products are permitted), reducing ambiguity for compliant businesses and shoppers.
Consumers and food producers are better protected because the bill explicitly bans clearly higher‑risk products (e.g., high‑dose oral or inhalable cannabinoids, synthetic cannabinoids, and food‑animal products) and gives FDA authority to inspect, detain, seize, and condemn unsafe cannabinoid hemp products.
The bill preserves and confirms existing FDA and HHS authorities over drugs, devices, and biologics, protecting established patient safety review processes and regulatory certainty for hospitals and health systems.
Small manufacturers, retailers, and other businesses face substantial compliance costs, potential product removals, and lost sales as products are reclassified, relabeled, tested, or prohibited under the new rules.
Some consumers will lose access to cannabinoid products they previously bought (including certain edibles or supplements) if those items exceed new thresholds or are reclassified as prohibited or drug products.
Giving the Secretary broad delegated authority to designate chemicals as cannabinoids can create regulatory uncertainty and sudden changes in product legality for companies until HHS updates its list.
Based on analysis of 5 sections of legislative text.
Establishes a federal regulatory regime for hemp‑derived cannabinoid products—defining covered compounds, requiring HHS to list cannabinoids, adding manufacturing/testing/age limits, expanded enforcement, and criminal penalties.
Creates a federal regulatory framework for hemp‑derived cannabinoid products by defining what counts as a “cannabinoid” and a “cannabinoid hemp product,” directing HHS/FDA to publish and maintain a list of covered cannabinoids, and treating those products as subject to the Food, Drug, and Cosmetic Act. It adds new manufacturing, testing, labeling and retail restrictions (including sales age limits), strengthens civil seizure/detention authority, and creates a new criminal penalty for knowing violations. Also renumbers an FD&C chapter and updates cross‑references, requires HHS to publish an initial cannabinoid list within one year, and includes a rule of construction preserving existing HHS/FDA authorities under the FD&C Act and the Public Health Service Act.